is semaglutide under patent Brazilian federal court denies extension Off-patent semaglutide in 2026: the

Novo Nordisk has launched Ozempic, a type-2 diabetes treatment, in India with a focus on affordable pricing and significant health benefits

If you came to struggle with gastroparesis, bowel obstruction or vision loss as a result of using Wegovy, we can help you with your claim

Drugmaker Novo Nordisk says it will make the popular weight GLP-1 weight loss medication Wegovy more affordable for those without insurance coverage, dropping the price to $349 a month.

These natural alternatives are cheaper, yet still effective for weight loss and blood sugar management without the hefty price tag and side effects of Ozempic.

GLP-3 is the catalog name